# Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis

> **NCT07192939** · PHASE2 · RECRUITING · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 270 (estimated)

## Conditions studied

- IPF and PPF

## Interventions

- **DRUG:** HRS-9813 capsules
- **DRUG:** HRS-9813 capsules
- **DRUG:** HRS-9813 capsule mimetic

## Key facts

- **NCT ID:** NCT07192939
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-29
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 270 (ESTIMATED)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07192939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07192939, "Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT07192939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*